Cite
HARVARD Citation
Verschraegen, C. et al. (2020). Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. Journal for immunotherapy of cancer. 8 (2), p. . [Online].